The Potential Risks of Long-Term Use of Spravato in Depression Treatment
Spravato (Esketamine), a nasal spray developed for treatment-resistant depression, has garnered significant attention since its FDA approval in 2019. As a rapidly acting antidepressant, Spravato offers a promising alternative for patients who have not found relief through traditional antidepressants.
However, as with any treatment, it is essential to consider the potential risks associated with long-term use.
https://medium.com/@shifahealt....h66/the-potential-ri
Like
Comment
Share
